These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 10632336)

  • 1. Prostate-specific membrane antigen levels in sera from healthy men and patients with benign prostate hyperplasia or prostate cancer.
    Beckett ML; Cazares LH; Vlahou A; Schellhammer PF; Wright GL
    Clin Cancer Res; 1999 Dec; 5(12):4034-40. PubMed ID: 10632336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease.
    Xiao Z; Adam BL; Cazares LH; Clements MA; Davis JW; Schellhammer PF; Dalmasso EA; Wright GL
    Cancer Res; 2001 Aug; 61(16):6029-33. PubMed ID: 11507047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measurement of serum prostate-specific membrane antigen, a new prognostic marker for prostate cancer.
    Murphy GP; Kenny GM; Ragde H; Wolfert RL; Boynton AL; Holmes EH; Misrock SL; Bartsch G; Klocker H; Pointner J; Reissigl A; McLeod DG; Douglas T; Morgan T; Gilbaugh J
    Urology; 1998 May; 51(5A Suppl):89-97. PubMed ID: 9610563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate-specific membrane antigen: current and future utility.
    Gregorakis AK; Holmes EH; Murphy GP
    Semin Urol Oncol; 1998 Feb; 16(1):2-12. PubMed ID: 9508077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PSA-PSMA profiles and their impact on sera PSA levels and angiogenic activity in hyperplasia and human prostate cancer.
    Ben Jemaa A; Bouraoui Y; Sallami S; Banasr A; Nouira Y; Oueslati R
    Pathol Biol (Paris); 2014 Jun; 62(3):129-36. PubMed ID: 24745345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of prostate specific membrane antigen, and prostate specific antigen levels in prostatic cancer patients.
    Murphy G; Ragde H; Kenny G; Barren R; Erickson S; Tjoa B; Boynton A; Holmes E; Gilbaugh J; Douglas T
    Anticancer Res; 1995; 15(4):1473-9. PubMed ID: 7544569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical significance of expression of PSA, hK2, PSMA in the peripheral blood of patients with prostate cancer].
    Cui WG; Zhao H; Song YZ; Zhang J; Zhang LG; Shi JD; Qiang WM
    Zhonghua Zhong Liu Za Zhi; 2004 Aug; 26(8):479-81. PubMed ID: 15555338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined nested reverse transcription-PCR assay for prostate-specific antigen and prostate-specific membrane antigen in detecting circulating prostatic cells.
    Zhang Y; Zippe CD; Van Lente F; Klein EA; Gupta MK
    Clin Cancer Res; 1997 Jul; 3(7):1215-20. PubMed ID: 9815802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation and comparison of two new prostate carcinoma markers. Free-prostate specific antigen and prostate specific membrane antigen.
    Murphy GP; Barren RJ; Erickson SJ; Bowes VA; Wolfert RL; Bartsch G; Klocker H; Pointner J; Reissigl A; McLeod DG; Douglas T; Morgan T; Kenny GM; Ragde H; Boynton AL; Holmes EH
    Cancer; 1996 Aug; 78(4):809-18. PubMed ID: 8756376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PSMA/PSA ratio evaluated by immunohistochemistry may improve diagnosis of prostate cancer.
    Jemaa AB; Bouraoui Y; Sallami S; Banasr A; Nouira Y; Oueslati R
    J Immunoassay Immunochem; 2014; 35(1):48-59. PubMed ID: 24063616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of prostate specific antigen, prostate specific membrane antigen, and LNCaP-based enzyme-linked immunosorbent assays in prostatic cancer patients and patients with benign prostatic enlargement.
    Murphy GP; Holmes EH; Boynton AL; Kenny GM; Ostenson RC; Erickson SJ; Barren RJ
    Prostate; 1995 Mar; 26(3):164-8. PubMed ID: 7534919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular staging of prostate cancer. II. A comparison of the application of an enhanced reverse transcriptase polymerase chain reaction assay for prostate specific antigen versus prostate specific membrane antigen.
    Cama C; Olsson CA; Raffo AJ; Perlman H; Buttyan R; O'Toole K; McMahon D; Benson MC; Katz AE
    J Urol; 1995 May; 153(5):1373-8. PubMed ID: 7536252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of serum PSMA, PSA levels with results of Cytogen-356 ProstaScint scanning in prostatic cancer patients.
    Murphy GP; Maguire RT; Rogers B; Partin AW; Nelp WB; Troychak MJ; Ragde H; Kenny GM; Barren RJ; Bowes VA; Gregorakis AK; Holmes EH; Boynton AL
    Prostate; 1997 Dec; 33(4):281-5. PubMed ID: 9397201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical role of prostate-specific membrane antigen (PSMA).
    Chang SS; Heston WD
    Urol Oncol; 2002; 7(1):7-12. PubMed ID: 12474535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of prostate specific membrane antigen and three alternatively spliced variants of PSMA in prostate cancer patients.
    Schmittgen TD; Teske S; Vessella RL; True LD; Zakrajsek BA
    Int J Cancer; 2003 Nov; 107(2):323-9. PubMed ID: 12949815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature.
    Chang SS; Reuter VE; Heston WD; Bander NH; Grauer LS; Gaudin PB
    Cancer Res; 1999 Jul; 59(13):3192-8. PubMed ID: 10397265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular distribution and heterogeneity of Psa and Psma expression in normal, hyperplasia and human prostate cancer.
    Ben Jemaa A; Bouraoui Y; Sallami S; Banasr A; Nouira Y; Horchani A; Oueslati R
    Tunis Med; 2013 Jul; 91(7):458-63. PubMed ID: 24008878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen.
    Murphy GP; Elgamal AA; Su SL; Bostwick DG; Holmes EH
    Cancer; 1998 Dec; 83(11):2259-69. PubMed ID: 9840525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate-specific membrane antigen (PSMA): current benefits and future value.
    Elgamal AA; Holmes EH; Su SL; Tino WT; Simmons SJ; Peterson M; Greene TG; Boynton AL; Murphy GP
    Semin Surg Oncol; 2000; 18(1):10-6. PubMed ID: 10617892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Classification analyses for prostate cancer, benign prostate hyperplasia and healthy subjects by SERS-based immunoassay of multiple tumour markers.
    Zhou L; Liu Y; Wang F; Jia Z; Zhou J; Jiang T; Petti L; Chen Y; Xiong Q; Wang X
    Talanta; 2018 Oct; 188():238-244. PubMed ID: 30029370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.